tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

SUPN Stock Latest News

SUPN Earnings this Week: How Will it Perform?
Pre-EarningsSUPN Earnings this Week: How Will it Perform?
1d ago
SUPN
Promising Growth Prospects for Supernus Pharmaceuticals: Buy Rating Driven by Qelbree and Onapgo Market Opportunities
PremiumRatings
Promising Growth Prospects for Supernus Pharmaceuticals: Buy Rating Driven by Qelbree and Onapgo Market Opportunities
2M ago
SUPN
Serina Therapeutics initiated with a Buy at JonesResearch
PremiumThe Fly
Serina Therapeutics initiated with a Buy at JonesResearch
2M ago
SER
SUPN
Supernus Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
Supernus Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
2M ago
SUPN
Supernus Pharmaceuticals Reports Strong 2024 Financial Growth
PremiumCompany Announcements
Supernus Pharmaceuticals Reports Strong 2024 Financial Growth
2M ago
SUPN
Supernus Pharmaceuticals: Strong Buy Rating Backed by Qelbree’s Growth and Promising Revenue Outlook
PremiumRatingsSupernus Pharmaceuticals: Strong Buy Rating Backed by Qelbree’s Growth and Promising Revenue Outlook
2M ago
SUPN
Supernus reports Q4 EPS 27c, consensus 52c
Premium
The Fly
Supernus reports Q4 EPS 27c, consensus 52c
2M ago
SUPN
Supernus sees FY25 revenue $600M-$630M, consensus $622.27M
Premium
The Fly
Supernus sees FY25 revenue $600M-$630M, consensus $622.27M
2M ago
SUPN
Supernus Pharmaceuticals Updates Executive Compensation Packages
PremiumCompany Announcements
Supernus Pharmaceuticals Updates Executive Compensation Packages
2M ago
8K
SUPN
SUPN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
SUPN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
SUPN
Cantor downgrades Supernus on ‘disappointing’ depression study
PremiumThe Fly
Cantor downgrades Supernus on ‘disappointing’ depression study
3M ago
SUPN
Supernus downgraded to Neutral from Overweight at Cantor Fitzgerald
PremiumThe Fly
Supernus downgraded to Neutral from Overweight at Cantor Fitzgerald
3M ago
SUPN
Closing Bell Movers: Shift4 down 10%, Penumbra up 8% after results
PremiumThe FlyClosing Bell Movers: Shift4 down 10%, Penumbra up 8% after results
3M ago
CE
FLS
Supernus announces SPN-820 trial misses primary endpoint
Premium
The Fly
Supernus announces SPN-820 trial misses primary endpoint
3M ago
SUPN
Supernus announces FDA approval of ONAPGO
Premium
The Fly
Supernus announces FDA approval of ONAPGO
3M ago
SUPN
Supernus announces U.S. FDA approved an update for label for Qelbree
PremiumThe Fly
Supernus announces U.S. FDA approved an update for label for Qelbree
3M ago
SUPN
Supernus initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Supernus initiated with an Overweight at Cantor Fitzgerald
4M ago
SUPN
Supernus initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Supernus initiated with an Overweight at Cantor Fitzgerald
4M ago
SUPN
Supernus Pharmaceuticals Reports Strong Q3 2024 Results
PremiumCompany Announcements
Supernus Pharmaceuticals Reports Strong Q3 2024 Results
6M ago
SUPN
Supernus reports Q3 EPS 69c, consensus 44c
PremiumThe FlySupernus reports Q3 EPS 69c, consensus 44c
6M ago
SUPN
Supernus raises 2024 revenue outlook to $630M-$650M from $600M-$625M
Premium
The Fly
Supernus raises 2024 revenue outlook to $630M-$650M from $600M-$625M
6M ago
SUPN
Supernus jumps 3% to $35.77 after Q3 beat, guidance raise
Premium
The Fly
Supernus jumps 3% to $35.77 after Q3 beat, guidance raise
6M ago
SUPN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >